| Sandpiper Speech And Language Therapy Llc | |
|
9160 Forum Corporate Parkway, Suite 350, Fort Myers, FL 33905 | |
| (239) 312-9001 | |
| (239) 206-5074 |
| Full Name | Sandpiper Speech And Language Therapy Llc |
|---|---|
| Type | Facility |
| Speciality | Clinic/center - Hearing And Speech |
| Location | 9160 Forum Corporate Parkway, Fort Myers, Florida |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063133205 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | (* (Not Available)) | Secondary |
| 261QH0700X | Clinic/center - Hearing And Speech | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Sandpiper Speech And Language Therapy Llc 4341 Lazio Way Apt 1203, Fort Myers, FL 33901-9622 Ph: () - | Sandpiper Speech And Language Therapy Llc 9160 Forum Corporate Parkway, Suite 350, Fort Myers, FL 33905 Ph: (239) 312-9001 |
News Archive
Climate change aggravates global health problems, above all for people in Africa. The group "Climate change and Health in Sub-Saharan Africa" funded by the German Research Foundation studies climate-induced damage to health in Burkina Faso and Kenya.
An industry-driven consortium has developed a national roadmap designed to chart the path to large-scale manufacturing of cell-based therapeutics for use in a broad range of illnesses including cancer, neuro-degenerative diseases, blood and vision disorders and organ regeneration and repair.
TxCell SA, a biotechnology company developing innovative, personalized cellular immunotherapies using regulatory T cells to treat severe chronic inflammatory and autoimmune diseases, today announces the signature of a strategic R&D collaboration agreement with the Lübeck Institute of Experimental Dermatology, a leading institution in the field of translational research on skin blistering diseases, part of the University of Lübeck in Germany.
Conmed Healthcare Management, Inc. today announced financial results for the three- and six-month periods ended June 30, 2011.
Alexza Pharmaceuticals, Inc. announced today that it has filed a universal shelf registration statement with the Securities and Exchange Commission (SEC) that, if declared effective by the SEC, will allow the Company to sell, from time to time, up to $75 million of its common stock, preferred stock, debt securities and/or warrants, either individually or in units, in one or more offerings.
› Verified 5 days ago